麻豆传媒

Latest negative results emphasize "critical" aspect of immunotherapy timing

With 98% PFS at 2 years, standard RT plus cisplatin sets a higher bar for de-escalation

Trial finds similar complication and recurrence rates with hypofractionated versus standard RT

Numerical advantage in randomized trial, non-randomized study misses noninferiority mark

In three trials, about 40% of patients with brain metastases recovered neurocognitive function

"It really shows us that we have two great options," expert says

Detectable circulating tumor DNA before radiotherapy linked with worse survival

Time to treatment completion slashed by over 4 hours compared with CT simulation planning

Randomized trial a "game changer" for patients who have implant-based reconstruction, expert says

Treatment over 1 to 2 weeks achieves similar outcomes to therapy given for as long as 7.5 weeks

Intercourse and/or vaginal dilation reduces risk of vaginal stenosis

Phase II study shows 100% local control and cancer-specific survival after more than 3 years

Radiotherapy led to "dramatic" slowing of progression, increased time with normal testosterone

SMART safe in patients with borderline or locally advanced cancer, with encouraging early OS data